January 22, 2014

High Stakes Intrigue In Hep C: Bristol-Myers Vs. Gilead

Provided by Seeking Alpha

Peter Geschek


Jan. 22, 2014 3:47 PM ET |  About: BMY, GILD

Gilead's (GILD) reluctance to marry its Hep C drug Sovaldi with Bristol-Myers Squibb's (BMY) daclatasvir forced Bristol to take evasive action.

Bristol applied to the European Union for approval of daclatasvir, an investigational NS5A complex inhibitor, for the treatment of adults with chronic hepatitis C with compensated liver disease, including genotypes 1, 2, 3, and 4. The application seeks the approval of daclatasvir for use in combination with other agents, including Sovaldi.

The EU accepted the application for an accelerated regulatory review. Hepatitis C represents a high unmet need in Europe where an estimated 9 million people are living with hepatitis C.

The EU submission follows a filing in Japan seeking approval for the treatment of patients infected with HCV genotype 1b.

Divorce before marriage

An article in the January New England Journal of Medicine presents great results from the combination trial of Sovaldi and daclatasvir.

Initially 44 previously untreated patients with genotype 1, 2 and 3 were tested with daclatasvir at a dose of 60 mg once daily tablet plus Sovaldi at a dose of 400 mg once daily tablet, with or without ribavirin, for 24 weeks.

Later on the study was expanded to include 123 additional patients with Genotype 1 infection. 82 patients were previously untreated and 41 patients had been previously treated with Incivek (made by Vertex (VRTX)) or Victrelis (made by Merck (MRK)) plus peginterferon alfa and ribavirin. The primary end point was a sustained virologic response (an HCV RNA level of lower than 25 IU per milliliter) at week 12 after the end of therapy.

The results represent, as is known from previous announcements, a breakthrough.

Overall, 211 patients were treated. Among patients with Genotype 1 infection, 98 percent of 126 previously untreated patients and 41 patients previously treated, had a sustained virologic response at week 12.

With Genotype 2 infection, 92 percent of the 26 patients and with Genotype 3, 89 percent of 18 patients had a sustained virologic response at week 12.

98 and 100 percent of sustained virologic response were observed among patients with HCV subtypes 1a and 1b and 93 and 98 percent with CC and non-CC genotypes.

The most common adverse events were fatigue, headache, and nausea.

In spite of the success, the companies haven't been able to agree on further testing of the combination.

Bristol's trials

Not getting any cooperation from Gilead, in January Bristol has started 3 Phase 3 trials on its own, testing daclatasvir and Sovaldi with a European submission in mind.

A very sick segment of the patient population will be enrolled.

The trial called Ally 1 is testing the drugs in patients with cirrhosis (end-stage liver disease) due to chronic HCV, and in patients who already had received a liver transplant.

All subjects will be treated with daclatasvir and Sovaldi for 12 weeks. The treatment may be extended for cirrhotic subjects. The plan is to enroll a total of 110 patients.

In arm 1a one 60 mg tablet of daclatasvir and one 400 mg Sovaldi tablet will be given each day to cirrhotic patients for 12 weeks.

Arm 1b is handling cirrhotic subjects who undergo transplant while in the study and require an extension. For these patients a ribavirin tablet will be added to the regimen, a daily dose of 1000-1200 mg in two divided doses for 12 weeks.

Arm 1c includes patients from arm 1b who relapsed and need further treatment for another 12 weeks.

Arm 2 of the trial is for post-transplant patients, a 12 week course. Primary outcome measure will be the proportion of Genotype 1 infected cirrhotic subjects who obtain SVR12, a sustained virologic response and the proportion of Genotype-1 post-transplant subjects with SVR12.

The trial called Ally 2 is to treat Hep C patients who also have an HIV infection.

All subjects are getting daclatasvir 30, 60 or 90 mg tablets and a Sovaldi 400 mg tablet daily. The first group includes new-to-treatment patients in a 12 weeks course, the second group is new-to-treatment patients treated for only 8 weeks and the third group comprises previously treated patients in a 12 weeks course. A total of 200 patients are planned to be recruited.

Ally 3 is focusing on Genotype 3 which has proven to be a tough subtype to treat in past trials.

One group is new-to-treatment, the other is previously treated patients with a total enrollment aimed at 150 people.

Bristol's strategy

Independent investigators like Graham Cooke at Imperial College London expressed the view that the Sovaldi/ledipasvir combination will probably be a winner in the large Genotype 1 population, but Genotype 3 patients could be better served with the Sovaldi/daclatasvir combination.

In other words, ledipasvir may be effective in patients with Genotype 1, the most common form worldwide, but it may not work so well for those with Genotype 3, which accounts for about 25 percent of cases in Europe and 45 percent in the U.K., and represents a sizable minority in other key markets in the world.

Bristol-Myers' strategy is seeking European approval for daclatasvir in order to pair it with Gilead's Sovaldi before Gilead gains clearance for its own combination. If the strategy works in Europe and the approved label is broad enough to include daclatasvir with Sovaldi, Bristol will try the same strategy in the U.S.

The European Union has large numbers of patients with HCV infection in urgent need of new treatment options. Due to the progressive nature of Hep C, decades may pass before patients start having symptoms. Many of these aging patients develop liver disease, making them more difficult to treat with the current standard of care of interferon plus ribavirin with or without a protease inhibitor.

Viral hepatitis has also been cited as a cause for the increase in HCC (hepatocellular carcinoma) in Europe.

Daclatasvir has been well studied now in more than 5,500 patients in a variety of all-oral regimens. The drug has shown potency against all genotypes, a low drug-on-drug interaction profile and has been well-tolerated in all investigational regimens and patient types without significant side effects.

Gilead's strategy

Gilead is developing an all Gilead-made combination in-house: it combines the approved Sovaldi with the experimental ledipasvir.

Gilead's justification for going alone is speed and expediency. Norbert Bischofberger, Gilead's head of research and development, stated in an e-mail sent to Bloomberg:

"We believe that we have been able to advance the development of this fixed-dose combination much more quickly than would have been possible with any inter-company collaboration. Gilead remains focused on delivering the simplest and safest all-oral treatment regimen to patients as quickly as possible."

He also said this in a press release:

"The results of the ION studies demonstrate that a simple, safe and short course of therapy with a single tablet regimen of sofosbuvir/ledipasvir can provide high cure rates among patients with genotype 1 HCV infection, while eliminating the need for both interferon and ribavirin. With the availability of these results, Gilead is finalizing its regulatory filing for sofosbuvir/ledipasvir, with the goal of submitting a New Drug Application in the first quarter of 2014."

After betting billions to come up with a new standard of care for Hep C ahead of all others, Gilead isn't likely to change its attitude toward the army of critics who claim that the company places business goals ahead of patients' interest.

When it was approved in December by the FDA, Gilead's Sovaldi became the first all-oral treatment for certain hepatitis C patients. Johnson & Johnson (JNJ) and Medivir AB also won FDA approval for their pill, Olysio, but this drug needs to be combined with other medicines, including some current treatments with undesirable side effects.

Gilead is testing other drugs, besides ledipasvir, to produce a full oral combination treatment, but those may not be available until the end of 2014 or the beginning of 2015.


According to the Centers for Disease Control and Prevention, about 3.2 million Americans are infected with the hepatitis C virus.

Hepatitis C is a viral disease that causes inflammation of the liver that can lead to diminished liver function or liver failure. Most people infected with the hepatitis C virus have no symptoms of the disease until liver damage becomes apparent, which may take several years. Most of these people then go on to develop chronic hepatitis C. Some will also develop scarring and poor liver function (cirrhosis) over many years, which can lead to complications such as bleeding, jaundice (yellowish eyes or skin), fluid accumulation in the abdomen, infections or liver cancer.

The race to develop hepatitis C pills is a part of a competition among drugmakers to find more convenient treatments that produce fewer side effects than current therapies, including injections. Since the viral infection can lead to liver cirrhosis, U.S. health officials recommended that every American born from 1945 to 1965 get tested for the disease.

The new combinations are projected to broaden the Hep C market which analysts estimate may reach $100 billion over a decade.

Investors' summary

Gilead: Gilead's Sovaldi, by itself, is priced at $84,000 per treatment, and is projected to sell $8.22 billion in 2016, according to an average of 11 analysts' estimates compiled by Bloomberg.

The Wholesaler Acquisition Cost of a 28-tablet bottle of Sovaldi in the U.S. is $28,000. If the Sovaldi/daclatasvir combination obtains regulatory approval, it almost certainly will become a blockbuster.

Bristol-Myers is focusing lately on antiviral treatments, cancer drugs and specialty medicines. It ended its work on diabetes treatments last month, selling a stake in a joint venture with U.K.- based AstraZeneca (AZN) for $4.3 billion.

Bristol's stock price ranged from $34.32 to $56.83 in the past 52 weeks, with investors appreciating the new, more promising direction of the company. Currently the price is positioned above both the 50 and 200 days simple moving averages.

Bristol-Myers Squibb Company is expected to report earnings on January 24th. Bloomberg's analyst poll forecasts $0.43 EPS for the fourth quarter, $1.74 for the whole year of 2013 based on a projected $16.3 billion annual earnings and an EPS of $1.77 based on $15.7 billion of projected earnings for 2014.

Regarding the Hep C race, it is too important for any of the participants to give up on it. Gilead may end up a winner in the race but Bristol-Myers Squibb certainly will do its utmost not to be left behind.

Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.


FDA Hepatitis Update - Victrelis (boceprevir) label changes update contraindications

You are receiving this message as a subscriber to the FDA hepatitis electronic list serve. The purpose of the list serve is to relay important information about viral hepatitis-related products and issues, including product approvals, significant labeling changes, safety warnings, notices of upcoming public meetings and alerts to proposed regulatory guidances for comment.
Please do not reply to this message.

On January 17, 2014, FDA approved changes to the Victrelis (boceprevir) package insert to expand the list of contraindicated medications and update the Drug Interaction section.

Doxazosin, silodosin and tamsulosin, alpha 1-adrenoreceptor antagonists, were added to the section 4Contraindications due to the potential for alpha 1-adrenoreceptor antagonist-associated adverse events such as hypotension and priapism.

In section 7 Drug Interactions the calcium channel blockers, amlodipine, dilitiazem, nisoldipine and verapamil were added.

The complete, revised label will be posted soon to the Drugs@FDA, and DailyMed sites.

Victrelis is a product of Merck & Co.

Richard Klein
Office of Health and Constituent Affairs
Food and Drug Administration

Kimberly Struble
Division of Antiviral Drug Products
Food and Drug Administration

If you are interested in receiving information about a broader range of FDA topics, consider subscribing to the FDAPatient Network News, a twice monthly electronic newsletter containing FDA-related information on a variety of topics, including new product approvals, significant labeling changes, safety warnings, notices of upcoming public meetings, proposed regulatory guidances and opportunity to comment, and other information of interest to patients and patient advocates.

This email was sent xxxx@yahoo.com using GovDelivery, on behalf of: U.S. Food & Drug Administration (FDA) · 10903 New Hampshire Ave · Silver Spring, MD 20993 · 800-439-1420


Bristol-Myers Squibb Hepatitis C Therapy Opens Up Combination Options

Provided by The Motley Fool

By Amy Ho | More Articles
January 22, 2014 | Comments (0)

In the race for new hepatitis C therapies, Bristol-Myers Squibb (NYSE: BMY ) is done courting Gilead (NASDAQ: GILD ) , maker of the first all-oral treatment for hepatitis C Sovaldi (sofosbuvir.)

Following Gilead's approval of Sovaldi, Bristol-Myers has long been trying to convince Gilead to join forces in a combination drug of sofosbuvir and Bristol-Myers' daclatasvir. However, Gilead has resisted a partnership and has maintained its potential combination drugs in-house.

With daclatasvir's approval pending in Europe, Bristol-Myers has garnered the confidence to break away from a possible partnership and piggyback its use with Gilead's sofosbuvir potentially off-label. Medically, the combination of daclatasvir and sofosbuvir has shown stellar results. Studies have shown that 12-week combination therapy cleared 100% of the virus in a study of 41 patients who were refractory to prior treatments of Incivek and Victrelis, gold standard treatments for hepatitis C .

Gilead's in-house sofosbuvir-ledipasvir combination has proven that it offers potentially better results for genotype 1, the major genotype of HCV. However, Bristol-Myers' proposed daclatasvir and sofosbuvir combination looks like it is preferential for the less prevalent, but still significant, population of patients with genotype 3. What it lacks in reach of patient population, Bristol-Myers has made up with in time – likely the European approval of daclatasvir will come before approval of Gilead's in-house combination.

For a market that analysts estimate to be worth $100 billion , there are multiple ways to slice the pie for the various players. That pie, however, may be more valuable to Bristol-Myers than Gilead. The former New York company recently backed out of the diabetes market after the sale of a $4.3 billion stake with AstraZeneca. With a narrower focus on antivirals, cancer treatments, and specialty medications, Bristol-Myers needs to dominate each one even more to reinforce its lofty valuation.

Nonetheless, Gilead is positioned to take the biggest stake of that market with the blockbuster Sovaldi priced at $84,000 per treatment course with estimated $8.22 billion in sales by 2016 . Gilead's impending combination therapies coming later this year can only help, so it is no wonder that the giant is not willing to partner with Bristol-Myers.

The two companies are far from the only players in the quickly crowding field, however.Johnson & Johnson (NYSE: JNJ ) actually gained FDA approval for its oral medication Olysio a month before Gilead's Sovaldi won approval. However, Johnson & Johnson's therapy targets a much smaller patient population based on efficacy with particular genotypes of hepatitis C.

Once daclatasvir gains approval, it will allow for off-label combinations for doctors satisfied with the existing studies on the combination. The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has already approved the use of a sofosbuvir-daclatasvir combination for compassion use in patients with genotype 1 who would otherwise be expected to die within a year. Executives at Bristol-Myers are hopeful that the movement in Europe will allow them to leverage the same in the United States. As such, while Gilead will still likely retain dominance for the prevalent genotype 1 hepatitis C market, Bristol-Myers may be able to effectively treat patients suffering from genotype 3. This would give the company a nice share of the market as well.

Dividend stocks can make you rich. It's as simple as that. While they don't garner the notoriety of high-flying growth stocks, they're also less likely to crash and burn. And over the long term, the compounding effect of the quarterly payouts, as well as their growth, adds up faster than most investors imagine. With this in mind, our analysts sat down to identify the absolute best of the best when it comes to rock-solid dividend stocks, drawing up a list in this free report of nine that fit the bill. To discover the identities of these companies before the rest of the market catches on, you can download this valuable free report by simply clicking here now.

Privacy/Legal Information

Fool contributor Amy Ho has no position in any stocks mentioned. The Motley Fool recommends Gilead Sciences and Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.


Paid Hepatitis C Clinical Trial Now Enrolling at Avail Clinical Research near Orlando, Florida; Accepting M/F Patients with Chronic Hepatitis C Age 18-65

Avail is conducting a randomized study to evaluate the safety and efficacy of a new hepatitis drug in combinations with simeprevir and/or ritonavir with or without Ribavirin for 12 weeks in participants with chronic hepatitis C infection.


DeLand, FL (PRWEB) January 22, 2014

*To see if you qualify for this Hepatitis C Clinical Trial in Florida, visit Avail Clinical Research on the web (http://www.availclinical.com) or contact us directly at (386) 785-2404. There is no cost to participate, no insurance is required, and you may receive compensation for time and travel.


The study will be conducted in three parts. Part A will utilize a randomized group design in treatment-naive, GT!b and 4 HCV-infected subjects. Sixty subjects will be enrolled and randomized to groups of equal size. GT!b and GT4 HCV-infected subjects will be stratified by genotype across the treatment arms. Each group will receive the study drugs for up to 12 weeks followed by a 24-week follow-up to determine sustained virologic response (SVR).

Part B will be a randomized, open-label, parallel-group design in treatment-naive, GT!b, 4 and 6 HCV-infected subjects. Enrollment into Part B will commence following enrollment completion of Part A. GT!b and GT4 HCV-infected subjects will be stratified by genotype between treatment arms in Cohorts I b and 2b. Per Amendment 5, enrollment into the I00 mg RBV-free arm was capped at the number of subjects who had already been dosed into that cohort, and RBV was immediately added to their treatment regimen.

Part C will be an open-label, randomized, parallel group design in treatment-naive or IFN/RBV-treatment relapsed, GT!a and GT!b HCV-infected subjects. An independent DSMB will review the available PK, safety, and antiviral activity data after all subjects have completed 4 weeks of treatment.


Hepatitis C virus (HCV) infection is a global public health problem. The global prevalence of chronic hepatitis C infection is estimated to be approximately 150 million HCV-infected persons worldwide. An estimated 60-70% of chronically infected people develop chronic liver disease; 5-20% develop cirrhosis and 1-5% die from cirrhosis or liver cancer. In 25% of liver cancer patients, the underlying cause is hepatitis C.

This new hepatitis C drug is being developed as a novel, HCV nonstructural protein S A (NSSA) inhibitor agent for the therapy of chronic hepatitis C. This drug acts as a potent inhibitor of HCV replication, inhibiting HCV of Genotypes (GT) l a, l b, 2a, 3a, 4a and Sa in vitro with half maximal effective concentration (ECso) values ranging from 2 to 24 pM, suggesting that it has pan-genotypic activity.


The primary objectives of this study are to evaluate the:

  • Safety and tolerability of 2- and 3-drug combinations of the new hepatitis C drug, simeprevir, ritonavir, with or without RBV for up to 12 weeks.
  • Efficacy of a 2-DAA combination treatment (new hepatitis drug and simeprevir) with RBV for up to 12 weeks.
  • Efficacy of a 3-DAA combination treatment (new hepatitis drug, simeprevir, ritonavir) with or without RBV for up to 12 weeks.


  • 18 to 65 years of age, inclusive.
  • Female subjects of both childbearing potential and non-childbearing potential may be included, unless the local regulatory authority requires that only females of non­ childbearing potential be included. Non-childbearing potential is defined as one of the following:
  • Postmenopausal, defined as amenorrheic for at least 2 years and serum follicle stimulating hormone (FSH) level consistent with postmenopausal status at Screening, OR
  • A documented hysterectomy, bilateral oophorectomy or bilateral tubal ligation at least 6 months prior to study initiation.
  • All female subjects must have a negative serum beta-human chorionic gonadotropin (P-HCG) at Screening and a negative urine pregnancy test prior to the first dose of study medication on Day J.
  • Women of childbearing potential and men must have agreed to use an acceptable double method of birth control (one of which must be a barrier method) from Screening through at least 6 months after the last dose of study drugs.
  • The co-administration of RTV with ethinyl estradiol (oral or patch) may result in decreased contraceptive effectiveness. Women in Part C who are receiving estrogen­ based hormonal contraceptives, must agree to use alternate contraceptive measures for the estrogen-based contraceptive. They must still fulfill the requirement to use an acceptable double method of birth control (one of which must be a barrier method).
  • Male subjects must have agreed not to donate sperm from the first dose through at least 6 months after the last dose of study drugs.
  • QTcF interval: S 450 ms at Screening and prior to dosing on Day 1.
  • Documented clinical history compatible with chronic hepatitis C, including any one of the following:
  • Anti- HCV antibody positive at least 6 months prior to Screening or dosing, OR
  • HCV RNA present in plasma by a sensitive and specific assay at least 6 months prior to Screening or dosing, OR
  • HCV genotype at least 6 months prior to Screening or dosing, OR
  • Histologic evidence of chronic hepatitis C infection.
  • Plasma HCV RNA positive at Screening with minimal viral load according to genotype:
  • GTI a (Q80K negative), I b and 6 HCV RNA 2::5 log10 IU/mL
  • GT4 HCV RNA 2:: 4 log10 IU/mL
  • Documented absence of cirrhosis within 36 months of Screening or dosing (histology or non-invasive equivalent, according to local standard of care).
  • Subject is, in the opinion of the investigator, willing and able to comply with the protocol and all other study requirements.
  • Subject has provided written informed consent to participate in the study.
  • Avail Clinical Research conducts a variety of Clinical Trials in Florida. For more information about participating in a Hepatitis C Clinical Study, please visit our website or contact us directly at (386) 785-2404.